Our data suggest that the therapeutic mechanism of NMT is related to its ability to regulate ribosome function following stroke induced downregulation of RPL26, RPL17, RPL39, and RPS13 [32] and through the upregulation of Tuba and Rac1 that activate NWASP to regulate actin function and tight junction formation. The gene discussed is RAC1; the disease is stroke disorder.